Parkinsonism Induced By 1-Methyl-4-Phenyl-1, 2, 3, 6-Tetrahydropyridine (MPTP): Implications for Treatment and the Pathogenesis of Parkinson's Disease

Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques

Volumn 11, Issue S1, 1984, Pages 160-165

  William Langston, J ^a,b   Ballard, Phillip ^a,b  

^a SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BENZATROPINE MESILATE; BROMOCRIPTINE; BROMOCRIPTINE MESILATE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; LEVODOPA;

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPIPERIDINE; ADVERSE DRUG REACTION; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; DRUG THERAPY; DYSKINESIA; HUMAN; INTOXICATION; NERVOUS SYSTEM; NEUROTOXICITY; PARKINSONISM; THERAPY;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ADULT; CARBIDOPA; CASE REPORT; DRUG COMBINATIONS; FEMALE; HALLUCINATIONS; HUMAN; LEVODOPA; MALE; MOVEMENT DISORDERS; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY; PYRIDINES;

EID: 0021239393     PISSN: 03171671     EISSN: 20570155     Source Type: Journal    
DOI: 10.1017/S0317167100046333     Document Type: Article

References (19)

1. Barbeau A (1980) High-level levodopa therapy in severely akinetic parkinsonian patients: Twelve years later. In: Parkinsons Disease: Current Progress, Problems, and Management, Rinne UK, Klingler M, Stamm G (eds). Elsivier/North Holland Biomedical Press, Amsterdam, pp 229-239.
2. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ (1983) A primate model of parkinsoniam: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-l, 2, 3, 6-tetrahydropyridine. Proc Natl Acad Sci 80: 4546-4550. 6192438
3. David GC, Williams AC, Markey SP, Ebert MH, Caine ED, Reichert CM, Kopin IJ (1979) Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1: 249-254. 298352
4. Ezrin-Waters C, Seeman P (1978) L-Dopa reversal of hyperdopaminergic behavior. Life Sci 22: 1027-1032. 565450
5. Fahn S (1982) Fluctuations of disability in Parkinsons Disease: Pathophysiology. In: Movement Disorders, Marsden CD, Fahn S (eds). Butterworth Scientific, London, pp 123-145.
6. Forno LS (1982) Pathology of Parkinsons Disease, In: Movement Disorders, Marsden CD, Fahn S (eds). Butterworth Scientific, London, pp 25-40. AMBIGUOUS (1038 citations)
7. Friedhoff AJ, Bonnett K, Rosengartèn H (1977) Reversal of two manifestations of dopamine receptor supersensitivity by administration of L-dopa. Res Commun Chem Pathol Parmacol 16: 411-423.
8. Granerus AK (1978) Factors influencing the occurrence of “on-off” symptoms during long-term treatment with L-dopa. Acta Med Scand 203: 75-78. 626117
9. Hoehn MM, Yahr MD (1967) Parkinsonism: Onset, progression and mortality. Neurology 17: 427-442. 6067254
10. Klawans HL, Goetz C Nausidea PA, Weiner WJ (1977) Levodopa-induced dopamine receptorhypersensitivity. Ann Neurol 2: 125-129.
11. Lang AE, Meadows JC, Parkes JO, Marsden CD (1982) Early onset of the “on-off phenomenon in children with symptomatic Parkinsonism. J Neurol, Neurosurg and Psychiat 45: 823-825.
12. Langston JW, Ballard P, Tetrud JW, Irwin I (1983 a) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979-980. 6823561
13. Langston JW, Forno LS, Rebert CS, Irwin I (In press (b)) Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1, 2, 5, 6-tetrahydropyridine (MPTP) in the squirrel monkey. Brain Research.
14. Lesser RP, Fahn S, Snider SR. Cote LJ, Isgreen WP, Barrett RE (1979) Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 29: 1253-1260. 573405
15. Marsden CD, Parkes JD (1976) “On-off effects in patients with Parkinsons disease on chronic levodopa therapy. Lancet 1: 292-296. 55599
16. Mones RJ, Elizan TS, Siegel GJ (1971) Analysis of L-dopa induced dyskinesias in 51 patients with Parkinsonism. J Neurol Neurosurg Psychiat 34: 668-673. 5158780
17. Muenter MD, Tyce GM (1971) L-dopa therapy of Parkinsons disease: Plasma L-dopa concentrations, therapeutic response, and side effects. Mayo Clinic Proceedings 46: 231-239. 5573818
18. Shoulson I, Glaubiger GA, Chase TN (1975) On-off response: Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 25: 1144-1148. 812004
19. Sweet RD, McDowell FH (1975) Five years treatment of Parkinsons disease with levodopa: Therapeutic results and survival of 100 patients. Ann Intern Med 83: 456-463. 1166978